{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:28:54Z","timestamp":1757618934223,"version":"3.44.0"},"reference-count":23,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2019,2,19]]},"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1136\/ejhpharm-2018-001840","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T17:22:16Z","timestamp":1552929736000},"page":"346-349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Fingolimod in multiple sclerosis: profile of use in habitual practice"],"prefix":"10.1136","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8605-1313","authenticated-orcid":false,"given":"Noelia","family":"Fern\u00e1ndez Bargiela","sequence":"first","affiliation":[{"name":"Pharmacy Service, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC). Sergas. Universidade da Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mondelo Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC). Sergas. Universidade da Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Gim\u00e9nez Arufe","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC). Sergas. Universidade da Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Vizoso Hermida","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC). Sergas. Universidade da Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00edn Herranz","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC). Sergas. Universidade da Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"2025090703011574000_27.6.346.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"2025090703011574000_27.6.346.2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nrl.2016.02.026","article-title":"Consensus statement on the treatment of multiple sclerosis by the Spanish Society of neurology in 2016","volume":"32","author":"Garc\u00eda Merino","year":"2017","journal-title":"Neurologia"},{"key":"2025090703011574000_27.6.346.3","unstructured":"World Health Organization . Multiple Sclerosis International Federation. Atlas multiple sclerosis resources in the world 2008 [consultado 26 Jul 2017]. Disponible en. Available: http:\/\/ http:\/\/www.who.int\/mental_health\/neurology\/Atlas_MS_WEB.pdf"},{"key":"2025090703011574000_27.6.346.4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.33588\/rn.5107.2010571","article-title":"Epidemiolog\u00eda de la esclerosis m\u00faltiple en Portugal Y Espa\u00f1a","volume":"51","author":"De S\u00e1","year":"2010","journal-title":"Rev Neurol"},{"key":"2025090703011574000_27.6.346.5","doi-asserted-by":"crossref","unstructured":"Rae-Grant A , Day GS , Marrie RA , et al . Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018;90.doi:10.1212\/WNL.0000000000005347","DOI":"10.1212\/WNL.0000000000006735"},{"key":"2025090703011574000_27.6.346.6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"key":"2025090703011574000_27.6.346.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22426"},{"key":"2025090703011574000_27.6.346.8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"2025090703011574000_27.6.346.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2012.10.004"},{"key":"2025090703011574000_27.6.346.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00451.x"},{"key":"2025090703011574000_27.6.346.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"2025090703011574000_27.6.346.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"2025090703011574000_27.6.346.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"2025090703011574000_27.6.346.14","first-page":"500","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"131","author":"Remes","year":"2015","journal-title":"Duodecim"},{"key":"2025090703011574000_27.6.346.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.09.009"},{"key":"2025090703011574000_27.6.346.16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2015.10.015","article-title":"Safety and efficacy of fingolimod in clinical practice: the experience of an academic center in the Middle East","volume":"289","author":"Yamout","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2025090703011574000_27.6.346.17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-014-0185-z","article-title":"Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the National Multiple Sclerosis Registry in Kuwait","volume":"28","author":"Al-Hashel","year":"2014","journal-title":"CNS Drugs"},{"key":"2025090703011574000_27.6.346.18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","article-title":"Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy","volume":"38","author":"Laroni","year":"2017","journal-title":"Neurol Sci"},{"key":"2025090703011574000_27.6.346.19","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.33588\/rn.63S01.2016255","article-title":"Fingolimod: efectividad Y seguridad en La pr\u00e1ctica cl\u00ednica habitual. estudio observacional, retrospectivo Y multic\u00e9ntrico en Galicia","volume":"63","author":"Pato-Pato","year":"2016","journal-title":"Rev Neurol"},{"key":"2025090703011574000_27.6.346.20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513500551"},{"key":"2025090703011574000_27.6.346.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000084822.01372.AC"},{"key":"2025090703011574000_27.6.346.22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2016.04.002","article-title":"Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)","volume":"8","author":"Meissner","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2025090703011574000_27.6.346.23","doi-asserted-by":"crossref","unstructured":"Laroni A , Brogi D , Morra VB , et al . Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014;14.doi:10.1186\/1471-2377-14-65","DOI":"10.1186\/1471-2377-14-65"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2018-001840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:01:24Z","timestamp":1757239284000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2018-001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,10,23]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/ejhpharm-2018-001840"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2018-001840","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2019,3,18]]}}}